GASTROESOPHAGEAL ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Novartis halts early trial of targeted radiation drug for tough cancers
Disease control TerminatedThis was an early-stage study to test the safety and find the right dose of a new radioactive drug called 177Lu-FF58 for people with advanced pancreatic, stomach, or brain cancer. The drug is designed to deliver radiation directly to tumors. The study was terminated early, and it…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 04, 2026 02:20 UTC
-
New imaging tracer tested to light up Hard-to-See cancers
Diagnosis TerminatedThis early-stage study tested a new imaging agent called [68Ga]-FF58. The goal was to see if this tracer could effectively highlight specific aggressive cancers—including brain, stomach, and pancreatic tumors—during a PET scan. A small group of adult patients with these cancers r…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Apr 03, 2026 14:43 UTC